ERBB2 and extramammary Paget disease: Immunohistochemistry may be useful in discriminating primary EMPD (HER-2/neu positive, CDX2 negative) from EMPD secondary to anorectal adenocarcinoma (HER-2/neu negative, CDX2 positive), but not EMPD secondary to urothelial or prostatic malignancy [5].